Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
IOBT 
IO Biotech Inc (IOBT)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
09/15/2025: IOBT (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
5 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $8
1 Year Target Price $8
| 2 | Strong Buy |
| 3 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -77.24% | Avg. Invested days 17 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 09/15/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 137.03M USD | Price to earnings Ratio - | 1Y Target Price 8 |
Price to earnings Ratio - | 1Y Target Price 8 | ||
Volume (30-day avg) 5 | Beta 0.41 | 52 Weeks Range 0.66 - 2.79 | Updated Date 09/15/2025 |
52 Weeks Range 0.66 - 2.79 | Updated Date 09/15/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.58 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -80.63% | Return on Equity (TTM) -212.51% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 117257301 | Price to Sales(TTM) - |
Enterprise Value 117257301 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA 1.36 | Shares Outstanding 65880900 | Shares Floating 34636891 |
Shares Outstanding 65880900 | Shares Floating 34636891 | ||
Percent Insiders 0.36 | Percent Institutions 63.84 |
Upturn AI SWOT
IO Biotech Inc
Company Overview
History and Background
IO Biotech Inc. is a clinical-stage biopharmaceutical company focused on developing immunotherapies to treat cancer. Founded in 2013, the company leverages its T-winu00ae platform to design immune-modulating cancer therapies. It went public in 2020.
Core Business Areas
- Cancer Immunotherapy Development: Focuses on discovering and developing novel cancer immunotherapies targeting the tumor microenvironment.
- T-winu00ae Platform: Utilizes the T-winu00ae platform to identify and develop immune-modulating therapies.
Leadership and Structure
The leadership team consists of senior executives with experience in biopharmaceutical research, development, and commercialization. The company has a typical biopharmaceutical organizational structure with departments focusing on research, clinical development, regulatory affairs, and finance.
Top Products and Market Share
Key Offerings
- IO102-IO103: A combination therapy targeting IDO and PD-L1. It is currently in Phase 3 trials for melanoma and Phase 2 trials for NSCLC and other cancers. Market share data is not publicly available as the product is in development. Competitors include pharmaceutical companies developing IDO or PD-L1 inhibitors such as Bristol Myers Squibb and Merck.
- IO202: A cancer vaccine based on the T-win platform. It is currently in Phase 1/2 trials. Market share data is not publicly available as the product is in development. Competitors include pharmaceutical companies developing cancer vaccines such as BioNTech and Moderna.
Market Dynamics
Industry Overview
The cancer immunotherapy market is experiencing substantial growth, driven by the increasing prevalence of cancer and the development of novel immunotherapeutic approaches. Key trends include the development of combination therapies and personalized medicine.
Positioning
IO Biotech is positioned as an innovator in the cancer immunotherapy space, focusing on modulating the tumor microenvironment to enhance immune responses. Its competitive advantage lies in its T-winu00ae platform and its focus on combination therapies.
Total Addressable Market (TAM)
The global cancer immunotherapy market is projected to reach hundreds of billions of dollars in the coming years. IO Biotech is targeting specific segments of this market with its therapies, including melanoma and NSCLC. The TAM for IO Biotech's products depends on the success of its clinical trials and regulatory approvals.
Upturn SWOT Analysis
Strengths
- Proprietary T-winu00ae platform
- Strong focus on combination therapies
- Experienced leadership team
- Novel approach to modulating the tumor microenvironment
Weaknesses
- Limited commercialized products
- Dependence on clinical trial success
- Competition from larger pharmaceutical companies
- Relatively small market capitalization
Opportunities
- Expansion into new cancer indications
- Partnerships with larger pharmaceutical companies
- Potential for breakthrough therapies
- Increasing adoption of cancer immunotherapy
Threats
- Clinical trial failures
- Regulatory hurdles
- Competition from existing therapies
- Pricing pressures
Competitors and Market Share
Key Competitors
- BMY
- MRK
- PFE
- AZN
Competitive Landscape
IO Biotech competes with larger pharmaceutical companies in the cancer immunotherapy space. Its advantage lies in its unique T-winu00ae platform and focus on combination therapies, but it faces challenges due to its smaller size and limited resources.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is measured by progress in clinical trials and expansion of the product pipeline.
Future Projections: Future growth is dependent on the success of its clinical trials and the potential for regulatory approvals. Analyst estimates vary based on these factors.
Recent Initiatives: Recent initiatives include advancing the clinical development of IO102-IO103 and IO202, and exploring partnerships with other companies.
Summary
IO Biotech is a clinical-stage company with a promising T-winu00ae platform. The success hinges on the results of ongoing clinical trials, especially IO102-IO103. The company needs to secure partnerships and funding for sustained growth. It faces strong competition from established players in the immunotherapy market.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company website
- SEC filings
- Analyst reports
- ClinicalTrials.gov
Disclaimers:
This analysis is for informational purposes only and should not be considered financial advice. Investment decisions should be based on individual due diligence and consultation with a financial advisor. Market share data is based on estimates and may not be precise.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About IO Biotech Inc
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2021-11-05 | Founder, President, CEO, Principal Financial Officer & Director Dr. Mai-Britt Zocca Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 78 | Website https://www.iobiotech.com |
Full time employees 78 | Website https://www.iobiotech.com | ||
IO Biotech, Inc., a clinical-stage biopharmaceutical company, develops immune-modulating therapeutic cancer vaccines based on the T-win technology platform. The company's lead therapeutic cancer vaccine candidate includes IO102-IO103, which targets cancer cells and immune-suppressive cells in the tumor microenvironment that express indoleamine 2,3-dehydrogenase (IDO), and programmed death-ligand (PD-L1) that is in phase 3 clinical trial to treat melanoma, as well as in phase 2 clinical trial to treat lung, head and neck, and melanoma cancer. It also develops IO112, a product candidate that contains a single Arginase 1-derived peptide to target T cells that recognize epitopes derived from Arginase 1, which is an immunoregulatory enzyme highly expressed in difficult-to-treat tumors associated with high levels of myeloid-derived suppressor cells, including renal cell carcinoma, head and neck, breast, pancreatic, ovarian, colorectal, and prostate cancers. In addition, the company develops IO170, a TGFß1 vaccine for the treatment of solid tumors. IO Biotech, Inc. was incorporated in 2014 and is based in Copenhagen, Denmark.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.